![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » FDA Accepts ImmunoGen’s BLA of Mirvetuximab Soravtansine for Ovarian Cancer
FDA Accepts ImmunoGen’s BLA of Mirvetuximab Soravtansine for Ovarian Cancer
May 25, 2022
The FDA has granted a priority review for ImmunoGen’s Biologics License Application (BLA) for its investigational antibody-drug conjugate, mirvetuximab soravtansine, as a monotherapy for patients with previously treated folate receptor alpha-high platinum-resistant ovarian cancer.
The company is also seeking an accelerated approval for the BLA supported by positive data a late-stage trial that demonstrated a response rate of 32.4 percent.
ImmunoGen is conducting an additional study that could potentially allow the accelerated approval to become a full approval. The company expects to release data from this study in early 2023.
The Priority Review designation means the FDA aims to make a decision on the application within six months instead of the standard 10 months. The agency’s Prescription Drug User Fee Act decision date for the BLA is Nov. 28, 2022.
Upcoming Events
-
21Oct